EX-99.14

EX-99.14 15 d20922dex9914.htm EX-99.14 EX-99.14

Exhibit 99.14

LOGO

IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JULY 31, 2019 AND 2018

(Unaudited – Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited condensed interim consolidated financial statements of the Company and all information contained in the first quarter 2020 report have been prepared by and are the responsibility of the Company’s management.

The Audit Committee of the Board of Directors has reviewed the condensed interim consolidated financial statements and related financial reporting matters.

The Company’s independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of condensed interim consolidated financial statements by an entity’s auditor.

IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited – Expressed in Canadian Dollars)


	Note	July 31, 2019 $			April 30, 2019 $
ASSETS
Current assets
Cash			4,951,871			5,471,650
Amounts receivable			1,341,193			1,558,354
Inventory			2,019,068			2,120,814
Unbilled revenue			237,481			393,451
Prepaid expenses			318,530			333,702

			8,868,143			9,877,971
Restricted cash			36,916			67,450
Investment	7		90,404			90,404
Property and equipment	8		3,075,172			1,638,549
Intangible assets	6, 7, 9		7,776,735			8,417,231
Goodwill	5, 6		8,019,458			8,254,114

Total assets			27,866,828			28,345,719

LIABILITIES
Current liabilities
Accounts payable and accrued liabilities	14		1,274,988			1,594,062
Taxes payable			168,800			27,268
Deferred revenue			813,821			724,693
Debentures	10		2,804,090			2,708,334
Loans payable	11		77,304			82,953
Leases	12		341,597			35,757
Deferred acquisition payments	5, 6		1,973,491			2,031,237

			7,454,091			7,204,304
Loans payable	11		13,968			28,717
Leases	12		1,383,682			71,320
Deferred acquisition payments	5, 6		1,428,644			1,032,744
Deferred income tax liability			1,884,419			1,939,559

			12,164,804			10,276,644

SHAREHOLDERS’ EQUITY
Share capital	13		32,725,780			32,699,425
Subscriptions received	13		1,500			—
Contributed surplus	13		3,348,832			3,074,192
Accumulated other comprehensive loss			(830,664	)		(228,060	)
Deficit			(19,543,424	)		(17,476,482	)

			15,702,024			18,069,075

Total liabilities and equity			27,866,828			28,345,719

Nature of operations (Note 1)

Commitments (Note 15)

Approved and authorized on behalf of the Board of Directors on September 26, 2019

“James Kuo” Director “Greg Smith” Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements

IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)


	Note		2019 $			2018 $
REVENUE				2,716,099			2,872,785
COST OF SALES				1,339,693			1,304,959

GROSS PROFIT				1,376,406			1,567,826

EXPENSES
Advertising				117,200			53,769
Amortization and depreciation		8, 9		547,841			175,562
Consulting fees				22,340			163,320
Foreign exchange gain				(112,976	)		(82,490	)
Insurance				20,531			12,055
Interest and bank charges				118,960			118,431
Management fees		14		45,148			46,298
Office and general				223,335			143,540
Professional fees		14		149,720			277,803
Rent				41,165			103,362
Repairs and maintenance				—			72,743
Research and development				167,260			31,788
Salaries and benefits		14		1,096,244			927,039
Share-based payments		13, 14		285,995			311,700
Telephone and utilities				10,100			10,764
Travel				119,305			73,028

				2,852,168			2,438,712

Loss before other income (expense) and income taxes				(1,475,762	)		(870,886	)

OTHER INCOME (EXPENSE)
Accretion		5, 6, 9		(552,893	)		(237,539	)
Interest and other income				12,402			43,515

				(540,491	)		(194,024	)

Loss before income taxes				(2,016,253	)		(1,064,910	)
Income taxes				4,055			(37,452	)

NET LOSS FOR THE PERIOD				(2,012,198	)		(1,102,362	)

ITEMS THAT MAY BE RECLASSIFIED SUBSEQUENTLY TO LOSS
Exchange difference on translating foreign operations				(602,604	)		(384,967	)

COMPREHENSIVE LOSS FOR THE PERIOD				(2,614,802	)		(1,487,329	)

LOSS PER SHARE – BASIC AND DILUTED				(0.03	)		(0.02	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING				67,982,923			55,941,298

The accompanying notes are an integral part of these condensed interim consolidated financial statements

IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited – Expressed in Canadian dollars, except for share figures)


	Number of Shares		Share Capital $			Subscriptions Received $		Contributed Surplus $			Accumulated Other Comprehensive (Loss) Income $			Deficit $			Total $
Balance, April 30, 2018		55,474,178		20,455,112			—		1,707,738			277,090			(9,859,015	)		12,580,925
Shares issued pursuant to private placements		875,000		700,000			—		—			—			—			700,000
Cash issue costs and finders’ fees		—		(10,926	)		—		—			—			—			(10,926	)
Shares issued pursuant to option exercise		110,000		57,980			—		(24,980	)		—			—			33,000
Share-based payments		—		—			—		311,700			—			—			311,700
Comprehensive loss for the period		—		—			—		—			(384,967	)		(1,102,362	)		(1,487,329	)

Balance, July 31, 2018		56,459,178		21,202,166			—		1,994,458			(107,877	)		(10,961,377	)		12,127,370
Shares issued pursuant to private placements		9,102,500		9,102,500			—		—			—			—			9,102,500
Cash issue costs and finders’ fees		182,460		(277,578	)		—		—			—			—			(277,578	)
Adjustment to value of shares issued pursuant to acquisition of IPA Europe and Immulease		—		975,045			—		—			—			—			975,045
Shares issued pursuant to settlement of Debentures		1,377,000		1,115,370			—		283,000			—			—			1,398,370
Shares issued pursuant to Crossbeta settlement		78,514		61,241			—		—			—			—			61,241
Shares issued pursuant to deferred acquisition payment to IPA Europe		714,793		507,503			—		—			—			—			507,503
Shares issued pursuant to option exercise		25,000		13,178			—		(5,678	)		—			—			7,500
Share-based payments		—		—			—		802,412			—			—			802,412
Comprehensive loss for the period		—		—			—		—			(120,183	)		(6,515,105	)		(6,635,288	)

Balance, April 30, 2019		67,939,445		32,699,425			—		3,074,192			(228,060	)		(17,476,482	)		18,069,075
Adoption of IFRS 16 (Note 3)		—		—			—		—			—			(54,744	)		(54,744	)

Balance, May 1, 2019		67,939,445		32,699,425			—		3,074,192			(228,060	)		(17,531,226	)		18,014,331
Shares issued pursuant to option exercise		50,000		26,355			—		(11,355	)		—			—			15,000
Subscriptions received		—		—			1,500		—			—			—			1,500
Share-based payments		—		—			—		285,995			—			—			285,995
Comprehensive loss for the period		—		—			—		—			(602,604	)		(2,012,198	)		(2,614,802	)

Balance, July 31, 2019		67,989,445		32,725,780			1,500		3,348,832			(830,664	)		(19,543,424	)		15,702,024

The accompanying notes are an integral part of these condensed interim consolidated financial statements

IMMUNOPRECISE ANTIBODIES LTD.

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)


	2019 $			2018 $
Operating activities:
Net loss for the period		(2,012,198	)		(1,102,362	)
Items not affecting cash:
Amortization and depreciation		702,284			220,007
Deferred income taxes		(55,140	)		(273,555	)
Accretion		552,893			237,539
Foreign exchange		(118,983	)		—
Share-based payments		285,995			311,700

		(645,149	)		(606,671	)
Changes in non-cash working capital related to operations:
Amounts receivable		217,161			398,221
Inventory		101,746			487
Unbilled revenue		155,970			259,246
Prepaid expenses		15,172			54,605
Accounts payable and accrued liabilities		(319,074	)		(290,719	)
Taxes payable		141,532			—
Deferred revenue		89,128			24,663

Net cash used in operating activities		(243,514	)		(160,168	)

Investing activities:
Purchase of equipment		(70,894	)		(24,099	)
Internally generated development costs		(10,621	)		—
Dividend received		—			5,460

Net cash used in investing activities		(81,515	)		(18,639	)

Financing activities:
Proceeds on share issuance		15,000			733,000
Share issuance costs		—			(10,926	)
Subscriptions received		1,500			—
Repayment of leases		(105,075	)		—
Proceeds from loans		—			200,000
Loan repayments		(20,398	)		(50,431	)

Net cash (used in) provided by financing activities		(108,973	)		871,643

(Decrease) increase in cash during the period		(434,002	)		692,836
Foreign exchange		(116,311	)		(137,945	)
Cash – beginning of the period		5,539,100			1,806,133

Cash – end of the period		4,988,787			2,361,024

Cash paid for interest		1,196			2,218
Cash paid for income tax		30,315			—

Supplemental cash flow information (Note 17)

The accompanying notes are an integral part of these condensed interim consolidated financial statements

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

1.	NATURE OF OPERATIONS

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) was incorporated under the laws of Alberta on November 22, 1983. The Company is listed on the TSX Venture Exchange (the “Exchange”) as a Tier 2 life science issuer under the trading symbol “IPA”. The Company’s OTC symbol is “IPATF”. The Company is a supplier of custom hybridoma development services. The address of the Company’s corporate office is 3204 – 4464 Markham Street, Victoria, BC, Canada V8Z 7X8.

The condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern. This assumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its obligations in the normal course of operations. The Company has incurred operating losses since inception, including $2,012,198 for the three months ended July 31, 2019 and has accumulated a deficit of $19,543,424 as at July 31, 2019. The Company may need to raise additional funds in order to continue on as a going concern and there can be no assurances that sufficient funding, including adequate financing, will be available. The ability of the Company to arrange additional financing in the future depends in part, on the prevailing capital market conditions and profitability of its operations. These material uncertainties may cast significant doubt on the Company’s ability to continue as a going concern. Accordingly, the condensed interim consolidated financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and liquidate its liabilities, contingent obligations and commitments other than in the normal course of business and at amounts different from those in the condensed interim consolidated financial statements.

2.	BASIS OF PRESENTATION

(a) Statement of compliance

These condensed interim consolidated financial statements have been prepared in conformity with International Accounting Standard (“IAS”) 34, Interim Financial Reporting, using the same accounting policies as detailed in the Company’s audited annual financial statements for the year ended April 30, 2019. They do not include all the information required for complete annual financial statements in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) and therefore should be read together with the audited annual financial statements for the year ended April 30, 2019.

These condensed interim consolidated financial statements were approved by the Board of Directors for issue on September 26, 2019.

(b) Basis of measurement

These condensed interim consolidated financial statements have been prepared on the historical cost basis. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for cashflow information.

(c) Basis of consolidation

These condensed interim consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company:

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)


Name of Subsidiary	% Equity Interest - 2020			% Equity Interest - 2019			Country of Incorporation
ImmunoPrecise Antibodies (Canada) Ltd. (formerly 0496106 B.C. Ltd.)		100	%		100	%	Canada
ImmunoPrecise Antibodies (USA) Ltd.		100	%		100	%	USA
ImmunoPrecise Antibodies (N.D.) Ltd.		100	%		100	%	USA
ImmunoPrecise Antibodies (MA) LLC		100	%		100	%	USA
Talem Therapeutics LLC		100	%		100	%	USA
U-Protein Express B.V. (“U-Protein”)		100	%		100	%	Netherlands
ImmunoPrecise Netherlands B.V.		100	%		100	%	Netherlands
ImmunoPrecise Antibodies (Europe) B.V. (“IPA Europe”, formerly ModiQuest Research B.V.)		100	%		100	%	Netherlands
Immulease B.V. (“Immulease”)		100	%		100	%	Netherlands

Control is achieved when the Company has the power to, directly or indirectly, govern the financial and operating policies of an entity so as to obtain benefits from its activities. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions and unrealized intercompany gains and losses are eliminated upon consolidation.

(d) Functional and presentation currency

The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements.

The functional currency of the Company and ImmunoPrecise Antibodies (Canada) Ltd. is the Canadian dollar. The functional currency of ImmunoPrecise Antibodies (USA) Ltd., ImmunoPrecise Antibodies (N.D.) Ltd., ImmunoPrecise Antibodies (MA) LLC and Talem Therapeutics LLC is the US dollar. The functional currency of U-Protein, ImmunoPrecise Netherlands BV, IPA Europe and Immulease is the Euro. The presentation currency of the Company is the Canadian dollar.

Entities whose functional currencies differ from the presentation currency are translated into Canadian dollars as follows: assets and liabilities – at the closing rate as at the reporting date, and income and expenses – at the average rate of the period. All resulting changes are recognized in other comprehensive income as cumulative translation differences.

Transactions in foreign currencies are translated into the functional currency at exchange rates at the date of the transactions. Foreign currency monetary assets and liabilities are translated at the functional currency exchange rate at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. All gains and losses on translation of these foreign currency transactions are included in profit or loss.

When the Company disposes of its entire interest in a foreign operation, or loses control, joint control, or significant influence over a foreign operation, the foreign currency gains or losses accumulated in other comprehensive income related to the foreign operation are recognized in profit or loss. If an entity disposes of part of an interest in a foreign operation which remains a subsidiary, a proportionate amount of foreign currency gains or losses accumulated in other comprehensive income related to the subsidiary are reallocated between controlling and non-controlling interests.

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

3.	ADOPTION OF NEW ACCOUNTING STANDARDS AND ACCOUNTING STANDARDS ISSUED BUT NOT YET EFFECTIVE

(a) Adoption of New Accounting Standards

The Company has adopted the following new standards, along with any consequential amendments, effective May 1, 2019. These changes were made in accordance with the applicable transitional provisions.

The Company adopted all of the requirements of IFRS 16, Leases (“IFRS 16”) as of May 1, 2019. IFRS 16 replaces IAS 17, Leases (“IAS 17”). IFRS 16 provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. The Company has adopted IFRS 16 using the modified retrospective application method, where the 2019 comparatives are not restated and a cumulative catch up adjustment is recorded on May 1, 2019 for any differences identified, including adjustments to opening deficit balance.

The Company analyzed its contracts to identify whether they contain a lease arrangement for the application of IFRS 16. The following is the Company’s new accounting policy for leases under IFRS 16:

At inception of a contract, the Company assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Leases of right-of-use assets are recognized at the lease commencement date at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined, and otherwise at the Company’s incremental borrowing rate. At the commencement date, a right-of-use asset is measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any decommissioning and restoration costs, less any lease incentives received.

Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures a right-of-use asset at cost less any accumulated depreciation and any accumulated impairment losses; and adjusted for any remeasurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset’s useful life and the lease term, except where the lease contains a bargain purchase option a right-of-use asset is depreciated over the asset’s useful life.

On the date of transition, the Company recorded a right-of-use asset of $1,668,533 related to the office rent in property and equipment, and the lease obligation of $1,723,277 was recorded as at May 1, 2019, discounted using the Company’s incremental borrowing rate of 8%, and measured at an amount equal to the lease obligation as if IFRS 16 had been applied since the commencement date. The net difference between right-of-use assets and lease liabilities on the date of transition was recognized as a deficit adjustment of $54,744 on May 1, 2019.

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

(b) Accounting Standards Issued But Not Yet Effective

In October 2018, the IASB issued amendments to IFRS 3, Business Combinations. The amendments narrowed and clarified the definition of a business. The amendments will help companies determine whether an acquisition is a business or a group of assets. They also permit a simplified assessment of whether an acquired set of activities and assets is a group of assets rather than a business. Distinguishing between a business and a group of assets is important because an acquirer recognizes goodwill only when acquiring a business. This amendment will be effective for annual periods beginning on or after January 1, 2020. Early adoption is permitted.

4.	CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS

The preparation of the condensed interim consolidated financial statements in conformity with IFRS required estimates and judgments that affect the amounts reported in the financial statements. Actual results could differ from these estimates and judgments. Estimates are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimate is revised. Significant areas requiring the use of estimates and judgments are as follows:

Functional currency

The Company has used judgment in determining the currency of the primary economic environment in which the entity operates.

Amounts receivable

The Company monitors the financial stability of its customers and the environment in which they operate to make estimates regarding the likelihood that the individual trade receivable balances will be paid. Credit risks for outstanding customer receivables are regularly assessed and allowances are recorded for estimated losses, if required.

Property and equipment

The Company has used estimates in the determination of the expected useful lives of property and equipment.

Revenue recognition

The percentage-of-completion method requires the use of estimates to determine the stage of completion which is used to determine the recorded amount of revenue, unbilled revenue and deferred revenue on uncompleted contracts. The determination of anticipated revenues includes the contractually agreed revenue and may also involve estimates of future revenues if such additional revenues can be reliably estimated and it is considered probable that they will be recovered. The determination of anticipated costs for completing a contract is based on estimates that can be affected by a variety of factors, including the cost of materials, labour, and sub-contractors. The determination of estimates is based on the Company’s business practices as well as its historical experience.

Impairments

For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (“cash generating units” or “CGU”s). Each asset or CGU is evaluated every reporting period to determine whether there are any indicators of impairment. If any such indicators exist, which is often judgment-based, a formal estimate of recoverable amount is performed and an impairment charge is recognized to the extent that the carrying amount exceeds the recoverable amount. The recoverable amount of an asset or CGU of assets is measured at the higher of fair value less costs of disposal or value in use. These determinations and their individual assumptions require that management make a decision based on the best available information at each reporting period. The estimates and assumptions are subject to risk and uncertainty; hence, there is the possibility that changes in circumstances will alter these projections, which may impact the recoverable amount of the assets. In such circumstances, some or all of the carrying value of the assets may be further impaired or the impairment charge reversed with the impact recorded in profit or loss.

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

The Company performs a goodwill impairment test annually and when circumstances indicate that the carrying value may not be recoverable. For the purposes of impairment testing, goodwill acquired through business combinations has been allocated to two different CGUs. The recoverable amount of each CGU was based on value in use, determined by discounting the future cash flows to be generated from the continuing use of the CGU. The cash flows were projected over a five-year period based on past experience and actual operating results.

The Company performed its annual goodwill impairment test in April 2019 and no impairment was indicated for the period tested. The values assigned to the key assumptions represented management’s assessment of future trends in the industry and were based on historical data from both internal and external sources. Weighted average costs of capital of 17.5% and 10.2%, respectively, was used in the assessments of the two CGUs.

Determination of segments

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. All operating segments’ results are reviewed by the Company’s management in order to make decisions regarding the allocation of resources to the segment. Segment results include items directly attributable to a segment as those that can be allocated on a reasonable basis.

As the Company provides antibody production and related services in one distinct category, there is only one category to report revenues by production site.

Life of intangible assets

Intangible assets are amortized based on estimated useful life less their estimated residual value. Significant assumptions are involved in the determination of useful life and residual values and no assurance can be given that actual useful lives and residual values will not differ significantly from current assumptions. Actual useful life and residual values may vary depending on a number of factors including internal technical evaluation, attributes of the assets and experience with similar assets. Changes to these estimates may affect the carrying value of assets, net income (loss) and comprehensive income (loss) in future periods.

Purchase price allocation

The acquisition of U-Protein on August 22, 2017 and the acquisition of IPA Europe and Immulease on April 5, 2018 were accounted for as business combinations at fair value in accordance with IFRS 3, Business Combinations. The acquired assets and assumed liabilities were adjusted to their fair values assigned through completion of a purchase price allocation, as described below.

The purchase price allocation process resulting from a business combination requires management to estimate the fair value of identifiable assets acquired including intangible assets and liabilities assumed including the deferred acquisition payment obligations. The Company uses valuation techniques, which are generally based on forecasted future net cash flows discounted to present value, and also relies on work performed by third-party valuation specialists. These valuations are closely linked to the assumptions used by management on the future performance of the related assets and the discount rates applied.

5.	ACQUISITION OF U-PROTEIN

On August 22, 2017, the Company completed the acquisition of U-Protein whereby the Company has acquired all of the issued and outstanding shares of U-Protein for €6,830,000 on terms as follows:

•

€2,734,732 (CAD$4,062,607) was paid in cash on closing;

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

•

3,030,503 common shares of the Company were issued on closing; and

•

€2,047,634 in deferred payments over a three-year period. The deferred payments can be made in cash or common shares of the Company at the election of U-Protein shareholders.

The transaction was accounted for as a business combination, as the operations of U-Protein meet the definition of a business. As the transaction was accounted for as a business combination, transaction costs of $17,717 were expensed. The goodwill resulting from the allocation of the purchase price to the total fair value of net assets represented the sales and growth potential of U-Protein. Goodwill recorded is allocated in its entirety to U-Protein. The fair value of the 3,030,503 common shares issued ($3,022,308) was determined based on the Canadian dollar equivalent of the consideration required of €2,047,634 pursuant to the share purchase agreement. The Company has allocated the purchase price as follows:


	$
Cash		4,062,607
3,030,503 common shares of the Company		3,022,308
Fair value of deferred payments		2,134,410

Fair value of consideration		9,219,325

Cash		797,276
Amounts receivable		370,530
Unbilled revenue		112,815
Inventory		36,900
Investment		90,404
Equipment, net of accumulated amortization		216,161
Intellectual property (not deductible for tax purposes)		4,064,000
Goodwill (not deductible for tax purposes)		4,655,893
Accounts payable and accrued liabilities		(269,657	)
Income taxes payable		(44,197	)
Deferred income tax liability		(810,800	)

		9,219,325

The deferred payments of €2,047,634 over a three-year period was fair valued on the date of acquisition using a discounted cash flow model. A discount rate of 16.3% was used. The changes in the value of the deferred payments during the three months ended July 31, 2019 and the year ended April 30, 2019 are as follows:


	$
Balance, April 30, 2018		2,408,205
Accretion expense		244,915
Payment		(1,049,754	)
Foreign exchange		(40,670	)

Balance, April 30, 2019		1,562,696
Accretion expense		284,166
Foreign exchange		(91,596	)

Balance, July 31, 2019		1,755,266

6.	ACQUISITION OF IPA EUROPE AND IMMULEASE

On April 5, 2018, the Company acquired all of the issued and outstanding shares of IPA Europe and its sister entity, Immulease, for an aggregate purchase price of €7,000,000 on terms as follows:

•

€2,500,000 (CAD$3,988,132) was paid in cash on closing;

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

•

6,600,399 common shares of the Company were issued on closing; and

•

€2,000,000 in deferred payments over a three-year period. The deferred payments will be made in three equal installments of cash and equity totaling €666,666 and will be prorated if the EBITDA of IPA Europe for the fiscal year preceding the date of payment is less than its average EBITDA over the previous two fiscal years. During the year ended April 30, 2019, the Company and the seller entered into an Amendment, Termination and Settlement Agreement whereby the deferred payments shall no longer be subject to an adjustment and will be paid in equal installments of cash and equity totaling €666,666.

The transaction was accounted for as a business combination, as the operations of IPA Europe and Immulease meet the definition of a business. As the transaction was accounted for as a business combination, transaction costs of $36,821 were expensed. The goodwill resulting from the allocation of the purchase price to the total fair value of net assets represented the sales and growth potential of IPA Europe. Goodwill recorded is allocated in its entirety to IPA Europe. The fair value of the 6,600,399 common shares issued ($4,884,295) was determined to be $0.74 per share based on the fair value of the Company’s shares immediately prior to the completion of the acquisition. The Company has allocated the purchase price as follows:


	$
Cash		3,988,132
6,600,399 common shares of the Company		4,884,295
Fair value of deferred payments		2,353,708

Fair value of consideration		11,226,135

Cash		270,339
Amounts receivable		572,427
Unbilled revenue		90,052
Inventory		2,286,995
Equipment, net of accumulated amortization		568,221
Software		30,974
Intangible assets (not deductible for tax purposes)		6,304,863
Goodwill (not deductible for tax purposes)		3,640,671
Accounts payable and accrued liabilities		(580,339	)
Deferred revenue		(22,897	)
Loans		(298,979	)
Deferred income tax liability		(1,636,192	)

		11,226,135

The deferred payments of €2,000,000 over a three-year period was fair valued on the date of acquisition using a discounted cash flow model. A discount rate of 10.1% was used. The changes in the value of the deferred payments during the three months ended July 31, 2019 and the year ended April 30, 2019 are as follows:


	$
Balance, April 30, 2018		2,403,954
Change in estimate of fair value		(34,258	)
Accretion expense		232,418
Payment		(1,014,503	)
Foreign exchange		(86,326	)

Balance, April 30, 2019		1,501,285
Accretion expense		172,971
Foreign exchange		(27,387	)

Balance, July 31, 2019		1,646,869

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

7.	INVESTMENT

Investment consists of a 29% (2019 – 29%) interest in QVQ Holding B.V. (“QVQ”), which is recorded at cost, being the best approximation of the investment’s fair value.

Judgment is required as to the extent of influence that the Company has over QVQ. The Company considered the extent of voting power over the entity, the power to participate in financial and operating policy decisions of the entity, representation on the board of directors, material transactions between the entities, interchange of management personnel, and provision of essential technical information. The Company has determined that the Company is not considered to have significant influence over QVQ, as the Company does not have the power to participate in financial and operating policy decisions, does not have representation on the Board of Directors of QVQ, and the majority of the common shares are held by QVQ management.

8.	PROPERTY AND EQUIPMENT


	Computer Hardware		Furniture & Equipment		Computer Software			Building		Leasehold Improvements		Lab Equipment			Total
	$		$		$			$		$		$			$
Cost:
Balance, April 30, 2018		93,813		98,527		12,373			—		393,421		2,787,105			3,385,239
Acquired on acquisition of IPA Europe		—		—		30,974			—		—		—			30,974
Additions		17,184		12,538		87,821			—		—		612,046			729,589
Foreign exchange		—		—		(1,153	)		—		—		(30,141	)		(31,294	)

Balance, April 30, 2019		110,997		111,065		130,015			—		393,421		3,369,010			4,114,508
Additions		3,952		—		—			1,668,533		—		66,942			1,739,427
Foreign exchange		—		—		(848	)		—		—		(54,746	)		(55,594	)

Balance, July 31, 2019		114,949		111,065		129,167			1,668,533		393,421		3,381,206			5,798,341

Accumulated Depreciation:
Balance, April 30, 2018		70,883		70,218		8,299			—		102,052		1,552,418			1,803,870
Depreciation		17,252		15,418		40,533			—		103,764		500,194			677,161
Foreign exchange		—		—		(43	)		—		—		(5,029	)		(5,072	)

Balance, April 30, 2019		88,135		85,636		48,789			—		205,816		2,047,583			2,475,959
Depreciation		4,905		1,803		23,938			108,920		17,588		125,408			282,562
Foreign exchange		—		—		(248	)		—		—		(35,104	)		(35,352	)

Balance, July 31, 2019		93,040		87,439		72,479			108,920		223,404		2,137,887			2,723,169

Net Book Value:
April 30, 2019		22,862		25,429		81,226			—		187,605		1,321,427			1,638,549
July 31, 2019		21,909		23,626		56,688			1,559,613		170,017		1,243,319			3,075,172

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

9.	INTANGIBLE ASSETS

The intangible assets were acquired as a result of the acquisitions of U-Protein and IPA Europe and are amortized using the straight-line method over their useful lives. The intellectual property has a useful life of 10 years, and the proprietary processes and certifications have a useful life of 5 years. The changes in the value of the intangible assets during the three months ended July 31, 2019 and the year ended April 30, 2019 are as follows:


	Internally Generated Development Costs			Intellectual Property			Proprietary Processes			Certifications			Total
	$			$			$			$			$
Cost:
Balance, April 30, 2018		—			4,270,229			—			—			4,270,229
Acquired on acquisition of IPA Europe		—			—			6,159,755			145,108			6,304,863
Foreign exchange		—			(125,004	)		(229,263	)		(5,401	)		(359,668	)

Balance, April 30, 2019		—			4,145,225			5,930,492			139,707			10,215,424
Additions		10,621			—			—			—			10,621
Foreign exchange		(205	)		(117,845	)		(168,598	)		(3,972	)		(290,620	)

Balance, July 31, 2019		10,416			4,027,380			5,761,894			135,735			9,935,425

Accumulated Amortization:
Balance, April 30, 2018		—			227,746			—			—			227,746
Amortization		—			416,890			1,169,233			—			1,586,123
Foreign exchange		—			(9,035	)		(6,641	)		—			(15,676	)

Balance, April 30, 2019		—			635,601			1,162,592			—			1,798,193
Amortization		—			102,667			317,055			—			419,722
Foreign exchange		—			(20,052	)		(39,173	)		—			(59,225	)

Balance, July 31, 2019		—			718,216			1,440,474			—			2,158,690

Net Book Value:
April 30, 2019		—			3,509,624			4,767,900			139,707			8,417,231
July 31, 2019		10,416			3,309,164			4,321,420			135,735			7,776,735

10.

DEBENTURES

On April 5, 2018, the Company completed a nonconvertible debenture (the “Debentures”) financing in the principal amount of $4,252,000 (the “Offering”). The Debentures are unsecured, bear interest at a rate of 10% per annum, payable semi-annually, and are due eighteen months from the date of issue. Under the Offering, a holder of a Debenture received 37,500 detachable share purchase warrants (the “Warrants”) for every $25,000 of Debentures subscribed for by the holder. The Warrants are exercisable at $0.70 per share for a period of four years from the date of issue. The fair value of the Debentures at the time of issue was calculated as the discounted cash flows assuming a 15% effective interest rate. The fair value of the Warrants was determined at the time of issue as the difference between the face value and the fair value of the Debentures. On initial recognition, the Company bifurcated $4,003,125 to the carrying value of the Debentures and $248,875 to the Warrants.

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

Under the Offering, the Company paid the following finder’s fees: $10,300 in cash, 580,320 shares of the Company with a fair value of $383,010, and 415,942 finder’s warrants valued at $187,627. The fair value of the finder’s warrants was estimated on the date of issue using the Black-Scholes option valuation model with the following weighted average assumptions: dividend yield of $nil, risk free interest rate of 1.60%, expected life of 4 years and expected volatility based on the historical volatility of similar companies of 100%. The total fair value of the finder’s fees was allocated pro-rata based on the carrying values of the Debentures and Warrants, with $546,934 allocated to the Debentures and $34,003 allocated to the Warrants.

On October 25, 2018, the Company settled $1,377,000 of the Debentures by issuing 1,377,000 units at a price of $1.00 per unit. Each unit consists of one common share of the Company and one share purchase warrant, with each warrant entitling the holder to purchase an additional share at $1.25 for two years. The fair value of the 1,377,000 common shares issued was determined to be $1,115,370. The fair value of the warrants issued was determined to be $283,000 and estimated on the date of issue using the Black-Scholes option valuation model with the following weighted average assumptions: dividend yield of $nil, risk free interest rate of 1.58%, expected life of 2 years and expected volatility based on the historical volatility of similar companies of 68.7%. The settlement resulted in a loss of $189,715.

During the three months ended July 31, 2019, the Company recorded accretion expense of $95,756 (2018 – $123,372). The changes in the value of the Debentures during the three months ended July 31, 2019 and the year ended April 30, 2019 are as follows:


	$
Balance, April 30, 2018		3,489,397
Accretion expense		427,592
Settlement of debentures		(1,208,655	)

Balance, April 30, 2019		2,708,334
Accretion expense		95,756

Balance, July 31, 2019		2,804,090

11.

LOANS PAYABLE

On April 5, 2018, the Company assumed loans payable of €60,750 (CAD$94,995) as a result of the acquisition of IPA Europe. On July 7, 2015, IPA Europe entered into a loan agreement in the principal amount of €165,000, maturing on July 31, 2020. The loan is secured by certain equipment, bears an interest rate of 4% per annum and is repayable in monthly installments of €2,250. The interest is owed per month in arrears. The principal outstanding at July 31, 2019 is €24,750 (CAD$36,202) (April 30, 2019 – €31,500 (CAD$47,423)).

On April 5, 2018, the Company assumed loans payable of €56,450 (CAD$88,271) as a result of the acquisition of IPA Europe. On February 1, 2016, IPA Europe entered into a loan agreement in the principal amount of €100,000, maturing on February 28, 2021. The loan is secured by certain equipment, bears an interest rate of 3% per annum and is repayable in monthly installments of €1,675. The interest is owed per month in arrears. The principal outstanding at July 31, 2019 is €29,650 (CAD$43,369) (April 30, 2019 – €34,675 (CAD$52,203)).

On April 5, 2018, the Company assumed loans payable of €74,000 (CAD$115,713) as a result of the acquisition of Immulease. On May 18, 2016, Immulease entered into a credit facility agreement pursuant to which the lender provides a facility amount of up to €200,000. The credit facility is unsecured, bears an interest rate of 3% per annum and is repayable on demand. The interest is owed per month in arrears. The principal outstanding at July 31, 2019 is €8,000 (CAD$11,701) (April 30, 2019 – €8,000 (CAD$12,044)).

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

On May 23, 2018, the Company entered into a loan agreement with a Director of the Company and his spouse and issued a promissory note in the principal amount of $200,000. The note was unsecured and bore an interest rate of 5.45% per annum. The principal of the note plus accrued interest of $3,972 was repaid in full during the year ended April 30, 2019.


	$
Balance, April 30, 2018		290,445
Loan proceeds		200,000
Loan repayments and foreign exchange		(378,775	)

Balance, April 30, 2019		111,670
Loan repayments and foreign exchange		(20,398	)

Balance, July 31, 2019		91,272
Current portion		(77,304	)

Non-current portion		13,968

12.

LEASES

The Company entered into certain equipment leases expiring between 2021 and 2023 with interest rates of between 13% and 17% per annum. The Company’s obligations under these finance leases are secured by the lessor’s title to the leased assets. The Company also entered into office leases in January 2018 and May 2018. With the adoption of IFRS 16, Leases (see Note 3), the Company recognized a lease obligation with regard to the office leases. The terms and the outstanding balances as at July 31, 2019 and April 30, 2019 are as follows:


	July 31, 2019 $			April 30, 2019 $
Equipment under finance lease repayable in monthly instalments of $1,228 with interests of between 13% and 17% per annum. Due dates are between May 2021 and March 2023.		98,527			107,077
Right-of-use asset from office lease repayable in monthly instalments of $21,015 and an interest rate of 8% per annum and an end date of April 2023.		835,958			—
Right-of-use asset from office lease repayable in monthly instalments of $22,012 and an interest rate of 8% per annum and an end date of December 2022.		790,794			—
Current portion		(341,597	)		(35,757	)

Non-current portion		1,383,682			71,320

As at July 31, 2019, the Company’s equipment includes a net carrying amount of $94,478 (April 30, 2019 – $104,014) for the leased equipment. The net carrying amount of the right-of-use assets from office lease obligation is $1,559,613 (April 30, 2019 – $nil).

The following is a schedule of the Company’s future minimum lease payments related to the equipment under finance lease and the office lease obligation:

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)


	$
2020		423,840
2021		565,122
2022		552,739
2023		446,989

Total minimum lease payments		1,988,690
Less: imputed interest		(263,411	)

Total present value of minimum lease payments		1,725,279
Less: Current portion		(341,597	)

Non-current portion		1,383,682

13.

SHARE CAPITAL

a) Authorized:

Unlimited common shares without par value.

b) Share capital transactions:

2019 Transactions

On June 19, 2018, the Company closed a non-brokered private placement financing by issuing a total of 875,000 units of the Company at a price of $0.80 per unit for gross proceeds of $700,000. Each unit consists of one common share of the Company and one share purchase warrant, with each warrant entitling the holder to purchase an additional share at a price of $1.00 for a period of one year from the date of issue. The Company will have the right to accelerate the expiry date of the warrants provided that the volume weighted average price trades at a price equal to or greater than $1.50 for a period of 20 consecutive days. In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after the Company issues a news release announcing that it has elected to exercise this acceleration right. All of the proceeds have been allocated to the common shares issued with a $nil value assigned to the warrants issued. The Company paid finders cash fees totaling $3,000 and incurred $7,926 of cash issue costs.

On September 24, 2018, the Company closed a non-brokered private placement financing by issuing a total of 9,102,500 units of the Company at a price of $1.00 per unit for gross proceeds of $9,102,500. Each unit consists of one common share of the Company and one share purchase warrant, with each warrant entitling the holder to purchase an additional share at a price of $1.25 for a period of two years from the date of issue. The Company will have the right to accelerate the expiry date of the warrants provided that the volume weighted average price trades at a price equal to or greater than $1.75 for a period of 20 consecutive days. In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after the Company issues a news release announcing that it has elected to exercise this acceleration right. All of the proceeds have been allocated to the common shares issued with a $nil value assigned to the warrants issued. The Company paid finders cash fees totaling $201,540 and issued 182,460 finder’s shares. The Company also incurred $76,038 of cash issue costs.

On December 22, 2017, the Company announced that it had signed a binding letter of intent with Crossbeta Biosciences B.V. (“Crossbeta”) whereby the Company had agreed to acquire all of the issued and outstanding shares of Crossbeta. The proposed transaction was terminated and settled on October 23, 2018. In consideration of the settlement, the Company paid €37,000 ($55,969) and issued 78,514 shares valued at $61,241. The Company accrued a settlement liability of $92,040 as at April 30, 2018. As such, the remaining loss on settlement of $25,170 was recognized in the year ended April 30, 2019.

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

On October 25, 2018, the Company settled $1,377,000 of the Debentures by issuing 1,377,000 units at a price of $1.00 per unit (Note 10). Each unit consists of one common share of the Company and one share purchase warrant, with each warrant entitling the holder to purchase an additional share at $1.25 for two years. The fair value of the 1,377,000 common shares issued was determined to be $1,115,370. The fair value of the warrants issued was determined to be $283,000 and estimated on the date of issue using the Black-Scholes option valuation model with the following weighted average assumptions: dividend yield of $nil, risk free interest rate of 1.58%, expected life of 2 years and expected volatility based on the historical volatility of similar companies of 68.7%. The settlement resulted in a loss of $189,715.

On March 27, 2019, the Company issued 714,793 common shares pursuant to the second deferred payment to IPA Europe (Note 6). The common shares are valued at $507,503.

During the year ended April 30, 2019, the Company issued 135,000 common shares pursuant to exercise of stock options for total gross proceeds of $40,500. A value of $30,658 was transferred from contributed surplus to share capital as a result. The weighted average share price at dates the stock options were exercised was $1.05.

2020 Transactions

During the three months ended July 31, 2019, the Company issued 50,000 common shares pursuant to exercise of stock options for total gross proceeds of $15,000. A value of $11,355 was transferred from contributed surplus to share capital as a result. The weighted average share price at dates the stock options were exercised was $0.69.

c) Escrow

There are 1,627,945 common shares of the Company held in escrow as at July 31, 2019. Under the Escrow Agreement, the common shares held in escrow will be released from escrow on December 29, 2019.

d) Options

The Company has an incentive Stock Option Plan (“the Plan”) under which non-transferable options to purchase common shares of the Company may be granted to directors, officers, employees or service providers of the Company. The terms of the plan provide that the Directors have the right to grant options to acquire common shares of the Company at not less than the closing market price of the shares on the day preceding the grant at terms of up to ten years. The maximum number of options outstanding under the Plan shall not result, at any time, in more than 10% of the issued and outstanding common shares.

On September 24, 2018, the Company granted 95,000 stock options, exercisable at $0.95 per option, to employees of the Company. The options are subject to vesting conditions as follows: one-third 6 months after grant date; one-third 12 months after grant date and one-third 18 months after grant date. The fair value of these options was estimated to be $67,402 using the Black-Scholes option pricing model and the following assumptions: dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 1.60%, and an expected life of 5 years.

On November 7, 2018, the Company granted 300,000 stock options, exercisable at $0.82 per option, to employees of the Company. The options are subject to vesting conditions as follows: one-third 6 months after grant date; one-third 12 months after grant date and one-third 18 months after grant date. The fair value of these options was estimated to be $184,658 using the Black-Scholes option pricing model and the following assumptions: dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 2.20%, and an expected life of 5 years.

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

On December 31, 2018, the Company granted 1,250,000 stock options, exercisable at $1.00 per option, to officers and directors of the Company. The options are subject to vesting conditions as follows: one-third 6 months after grant date; one-third 12 months after grant date and one-third 18 months after grant date. The fair value of these options was estimated to be $625,485 using the Black-Scholes option pricing model and the following assumptions: dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 2.20%, and an expected life of 5 years.

On January 11, 2019, the Company granted 415,000 stock options, exercisable at $1.00 per option, to officers and an employee of the Company. The options are subject to vesting conditions as follows: one-third 6 months after grant date; one-third 12 months after grant date and one-third 18 months after grant date. The fair value of these options was estimated to be $228,801 using the Black-Scholes option pricing model and the following assumptions: dividend yield of 0%, expected volatility of 100%, a risk-free interest rate of 2.20%, and an expected life of 5 years.

Expected volatility was based on the historical volatility of similar companies.

During the three months ended July 31, 2019 the Company has recorded $285,995 (2018 - $311,700) of share-based payments expense.

The changes in the stock options for the three months ended July 31, 2019 and the year ended April 30, 2019 are as follows:


	Number of options #			Weighted average exercise price $		Weighted average life remaining (years)
Balance, April 30, 2018		4,871,666			0.68		4.20
Granted		2,060,000			0.97		—
Exercised		(135,000	)		0.30		—
Expired		(200,000	)		1.24		—
Forfeited		(1,293,333	)		0.71		—

Balance, April 30, 2019		5,303,333			0.78		3.87
Exercised		(50,000	)		0.30		—
Forfeited		(50,000	)		1.01		—

Balance, July 31, 2019		5,203,333			0.78		3.64
Unvested		(1,606,667	)		0.90		4.27

Exercisable, July 31, 2019		3,596,666			0.73		3.35

Details of the options outstanding as at July 31, 2019 are as follows:


Expiry Date	Exercise price $		Remaining life (year)		Options outstanding		Unvested		Vested
December 20, 2021		0.30		2.39		658,333		—		658,333
September 18, 2022		1.01		3.14		1,035,000		—		1,035,000
January 3, 2023		0.65		3.43		750,000		—		750,000
February 7, 2023		0.47		3.53		700,000		233,333		466,667
September 24, 2023		0.95		4.15		95,000		63,333		31,667
November 7, 2023		0.82		4.27		300,000		200,000		100,000
December 31, 2023		1.00		4.42		1,250,000		833,334		416,666
January 11, 2024		1.00		4.45		415,000		276,667		138,333

		0.78		3.64		5,203,333		1,606,667		3,596,666

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

e) Warrants

The changes in the warrants for the three months ended July 31, 2019 and the year ended April 30, 2019 are as follows:

Number of
warrants
#

Weighted average
exercise price
$

Weighted average life
remaining (years)

Balance, April 30, 2018

6,378,000

0.70

3.93

Issued

11,354,500

1.23

—

Balance, April 30, 2019 and July 31, 2019

17,732,500

1.04

1.70

Details of the warrants outstanding as at July 31, 2019 are as follows:


Expiry Date	Exercise price $		Remaining life (year)		Warrants outstanding
March 26, 2022		0.70		2.68		6,378,000
June 18, 2020		1.00		0.88		875,000	⁽¹⁾
September 24, 2020		1.25		1.15		9,102,500
October 25, 2020		1.25		1.24		1,377,000

		1.04		1.70		17,732,500

⁽¹⁾

During the three months ended July 31, 2019, the expiry date of these warrants was extended from June 18, 2019 to June 18, 2020.

f) Finder’s Warrants

As at July 31, 2019 the Company has 415,942 finder’s warrants outstanding. The warrants have an exercise price of $0.70 per share and expire on March 26, 2022.

14.

RELATED PARTY TRANSACTIONS

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. Key management consists of Thomas D’Orazio, former President and CEO; Robert Beecroft, former Interim CEO; Dr. Jennifer Bath, President and CEO; Lisa Helbling, CFO; Natasha Tsai, former CFO; Reginald Beniac, former Chief Operating Officer; Charles Wheelock, Chief Technology Officer; Oren Beske, former President of ImmunoPrecise Antibodies (USA) Ltd.; Martin Hessing, a Director of U-Protein; Jos Raats, former President and CEO of IPA Europe; and Directors of the Company. During the three months ended July 31, 2019 and 2018, the compensation for key management is as follows:


	2019 $		2018 $
Management fees		45,148		103,980
Professional fees		—		13,075
Salaries and other short-term benefits		485,845		101,830
Share-based payments		264,882		175,092

		795,875		393,977

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)

During the three months ended July 31, 2019, the spouse of a Director provided administrative services for $nil (2018 – $15,625).

15.

COMMITMENTS

For the Company’s rental of office and laboratory space in Victoria, BC, Canada, the current lease commenced on May 1, 2018 and terminates on April 30, 2023. The lease is in the amount of $21,015 per month for all four spaces from May 1, 2018 to April 30, 2021 and $21,914 per month from May 1, 2021 to April 30, 2023. The minimum annual payments under these leases are as follows:


	$
2020		252,186
2021		252,186
2022		262,968
2023		262,968

		1,030,308

For the Company’s rental of office and laboratory space in Utrecht, Netherlands, the current lease commenced on January 1, 2017 and terminates on December 31, 2019. Annual minimum lease payments are as follows:


	€
2020		88,415

For the Company’s rental of office and laboratory space in Oss, Netherlands, the current lease commenced on January 1, 2018 and terminates on December 31, 2019. Effective December 31, 2018, the lease automatically rolls into a 3 year term through December 31, 2022. Annual minimum lease payments are as follows:


	€
2020		175,454
2021		175,454
2022		175,454
2023		116,970

		643,332

16.

SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE

At July 31, 2019 and April 30, 2019, the Company has one reportable segment, being antibody production and related services.

During the three months ended July 31, 2019, the Company had sales to nil (2018 - nil) customer who in aggregate accounted for more than 10% (2018 – 10%) of revenue.

The Company’s revenues are allocated to geographic segments for the three months ended July 31, 2019 and 2018 as follows:

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)


	2019 $		2018 $
United States of America		904,377		601,011
Canada		206,823		140,632
Europe		1,505,926		2,057,779
Other		98,973		73,363

		2,716,099		2,872,785

The Company’s revenues are allocated according to revenue types for the three months ended July 31, 2019 and 2018 as follows:


	2019 $		2018 $
Project revenue		2,611,868		2,760,773
Product sales revenue		60,234		30,941
Cryo storage revenue		43,997		81,071

		2,716,099		2,872,785

The Company’s non-current assets are allocated to geographic segments as at July 31, 2019 and April 30, 2019 as follows:


	July 31, 2019 $		April 30, 2019 $
North America		1,674,974		986,323
Netherlands		17,323,711		17,481,425

		18,998,685		18,467,748

Geographic segmentation of the Company’s (loss) income is as follows:


	2019 $			2018 $
North America - Corporate		(1,974,763	)		(600,917	)
North America		(112,064	)		(1,057,389	)
Netherlands		74,629			555,944

		(2,012,198	)		(1,102,362	)

Geographic segmentation of the interest and accretion, and amortization and depreciation is as follows:


Interest and accretion	2019 $		2018 $
North America - Corporate		630,675		345,959
North America		23,975		6,918
Netherlands		17,203		3,093

		671,853		355,970

IMMUNOPRECISE ANTIBODIES LTD.

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended July 31, 2019 and 2018

(Unaudited – Expressed in Canadian Dollars)


Amortization and depreciation	2019 $		2018 $
North America - Corporate		20,640		—
North America		126,771		36,559
Netherlands		554,873		183,448

		702,284		220,007

17.

SUPPLEMENTAL CASH FLOW INFORMATION


Non-cash investing and financing transactions:	July 31, 2019 $		July 31, 2018 $
Acquisition of equipment by capital lease		1,668,533		—

The following changes in liabilities arose from financing activities:


						Non-cash changes
	April 30, 2019 $		Cash Flows $			Acquisition $		Accretion $		Foreign exchange movements and change in estimates $			July 31, 2019 $
Deferred acquisition payments		3,063,981		—			—		457,137		(118,983	)		3,402,135
Debentures		2,708,334		—			—		95,756		—			2,804,090
Loans payable		111,670		(20,398	)		—		—		—			91,272
Leases		107,077		(105,075	)		1,723,277		—		—			1,725,279

Total		5,991,062		(125,473	)		1,723,277		552,893		(118,983	)		8,022,776

18.

SUBSEQUENT EVENTS

a) Exercise of Stock Options

Subsequent to the three months ended July 31, 2019, the Company issued 5,000 common shares pursuant to the exercise of stock options for total gross proceeds of $1,500.

b) Debentures

On September 26, 2019, the company modified the terms of $2,750,000 debentures to extend the due date 6 months to March 26, 2020, with the ability to pay earlier with no penalty, and increase the interest rate to 12.5%. The remaining debentures of $125,000 were paid on maturity.